Many observational studies have been unable to gather enough useful information.

The rapid evolution of DNA sequencing and correctness over the past 10 years has greatly improved our understanding of genes, but there are still great difficulties in collecting treatment data, and many observational studies have limited success because they are unable to gather enough useful information.

Solvebio, a start-up company dedicated to providing DNA integration data for hospitals, diagnostic devices, and bio-health researchers, recently announced that it had completed the first round of $2 million trillion in funding from Andreessen Horowitz, and that the cancer data service provider, Flatiron, The latter was funded by Google Ventures 130 million dollars.

Solvebio was founded only a year ago, initially from universities, health equipment organizations, various types of DNA data, and the decentralized, organized, and difficult to manage data to be parsed, organised, packaged, and opened to the medical research institutions that may be needed in the form of APIs.

Solvebio CEO Mark Kaganovich says the rules governing personal health data privacy are very stringent. So before you do data consolidation, Solvebio encodes and anonymously the individual data.